Alex Sparreboom

Alex Sparreboom

Alex Sparreboom, PhD

Unit / Department / Division
Pharmaceutics and Pharmacology
Outcomes and Translational Sciences Affiliated Faculty
408 Biomedical Research Tower
Email Address
Phone Number

Professional Interests

Professional Interests

Dr. Sparreboom's research studies the contribution of solute carriers to chemotherapy-induced toxicity profiles, identifies chemical inhibitors of critical transporters, translates the findings to clinical trials in collaboration with scientists and oncologists, and ultimately improves the long-term outcome of patients with cancer by modulating the therapeutic window of widely-used chemotherapeutics. His research is currently focused on the development of transport modulators that could be used in conjunction with platinum-based drugs and tyrosine-kinase inhibitors, with emphasis on the development of innovative preclinical model systems.


  • PhD, 1996, The Netherlands Cancer Institute/Utrecht University, Pharmacy
  • MSc, 1993, Utrecht University, Pharmacy
  • BSc, 1989, Utrecht University, Pharmacy

Journal Articles

Uddin ME, Moseley A, Hu S, Sparreboom A. Contribution of Membrane Transporters to Chemotherapy-Induced Cardiotoxicity. Basic Clin Pharmacol Toxicol. 2021 Jul 8. doi: 10.1111/bcpt.13635. Epub ahead of print. PMID: 34237188. 

Marie S, Hernández-Lozano I, Breuil L, Truillet C, Hu S, Sparreboom A, Tournier N, Langer O. Imaging-Based Characterization of a Mouse Model Using Erlotinib and Mebrofenin as Probe Substrates. Pharmaceutics. 2021 Jun 21;13(6):918. doi: 10.3390/pharmaceutics13060918. PMID: 34205780; PMCID: PMC8233734. 

Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, Hecht DP, Klute KA, Morrison VA, Pini TM, Rosner GL, Runowicz CD, Shayne M, Sparreboom A, Turner S, Zarwan C, Lyman GH. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Jun 20;39(18):2037-2048. doi: 10.1200/JCO.21.00471. Epub 2021 May 3. PMID: 33939491. 

Eisenmann ED, Talebi Z, Sparreboom A, Baker SD. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2021 Jun 12. doi: 10.1111/bcpt.13623. Epub ahead of print. PMID: 34117715.  

Jin Y, Li Y, Uddin ME, Sparreboom A, Hu S. Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Apr 1;1168:122591. doi: 10.1016/j.jchromb.2021.122591. Epub 2021 Feb 21. PMID: 33684722; PMCID: PMC7987214. 

Uddin ME, Garrison DA, Kim K, Jin Y, Eisenmann ED, Huang KM, Gibson AA, Hu Z, Sparreboom A, Hu S. Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1. Front Pharmacol. 2021 Mar 8;12:644342. doi: 10.3389/fphar.2021.644342. PMID: 33790797; PMCID: PMC8006202. 

Hayden ER, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA. Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation. Clin Cancer Res. 2021 Mar 4. doi: 10.1158/1078-0432.CCR-21-0023. Epub ahead of print. PMID: 33664059. 

Stage TB, Hu S, Sparreboom A, Kroetz DL. Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy. Clin Transl Sci. 2021 Mar;14(2):460-467. doi: 10.1111/cts.12915. Epub 2020 Nov 9. PMID: 33142018; PMCID: PMC7993259. 

Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):e2020168118. doi: 10.1073/pnas.2020168118. PMID: 33495337; PMCID: PMC7865186. 

Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Clin Transl Sci. 2021 Jan;14(1):137-142. doi: 10.1111/cts.12861. Epub 2020 Sep 9. PMID: 32905646; PMCID: PMC7877866. 

Mout L, Moll JM, Chen M, de Morrée ES, de Ridder CMA, Gibson A, Stuurman D, Aghai A, Erkens-Schulze S, Mathijssen RHJ, Sparreboom A, de Wit R, Lolkema MP, van Weerden WM. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer. Br J Cancer. 2020 Dec;123(12):1715-1719. doi: 10.1038/s41416-020-01105-y. Epub 2020 Sep 29. PMID: 32989230; PMCID: PMC7722857. 

Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson AA, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg MB, Cavaletti G, Pabla N, Hu S, Sparreboom A. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J Clin Invest. 2020 Sep 1;130(9):4601-4606. doi: 10.1172/JCI136796. PMID: 32484793; PMCID: PMC7456253. 

Eisenmann ED, Jin Y, Weber RH, Sparreboom A, Baker SD. Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122176. doi: 10.1016/j.jchromb.2020.122176. Epub 2020 May 20. PMID: 32534260. 

Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceutics. 2020 Aug 20;12(9):788. doi: 10.3390/pharmaceutics12090788. PMID: 32825359; PMCID: PMC7559746. 

Anderson JT, Huang KM, Lustberg MB, Sparreboom A, Hu S. Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions. Rev Physiol Biochem Pharmacol. 2020 Aug 7:10.1007/112_2020_30. doi: 10.1007/112_2020_30. Epub ahead of print. PMID: 32761456; PMCID: PMC7902122. 

Atrafi F, van Eerden RAG, van Hylckama Vlieg MAM, Oomen-de Hoop E, de Bruijn P, Lolkema MP, Moelker A, Rijcken CJ, Hanssen R, Sparreboom A, Eskens FALM, Mathijssen RHJ, Koolen SLW. Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. Clin Cancer Res. 2020 Jul 15;26(14):3537-3545. doi: 10.1158/1078-0432.CCR-20-0008. Epub 2020 Apr 22. PMID: 32321718.